ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
| 54.70 Delayed Data As of Dec 02 |  -2.09 / -3.68%Today’s Change | 30.02 Today|||52-Week Range 58.72 | +27.86% Year-to-Date |
Latest ACAD News | Press Releases
No recent news for ACADIA Pharmaceuticals Inc.
Today’s Trading
| Previous close | 56.79 |
| Today’s open | 56.39 |
| Day’s range | 54.29 - 56.41 |
| Volume | 58,153 |
| Average volume (3 months) | 1,166,385 |
| Market cap | $8.9B |
Data as of 4:01pm ET, 12/02/2020
Growth & Valuation
| Earnings growth (last year) | +17.49% |
| Earnings growth (this year) | -14.52% |
| Earnings growth (next 5 years) | -66.40% |
| Revenue growth (last year) | +51.50% |
| P/E ratio | NM |
| Price/Sales | 18.57 |
| Price/Book | 12.44 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| GLPGGalapagos NV | -2.49 | -1.96% |
| JAZZJazz Pharmaceuticals... | +1.36 | +0.95% |
| RGENRepligen Corp | -6.78 | -3.50% |
| RAREUltragenyx Pharmaceu... | +0.33 | +0.28% |
Data as of 3:59pm ET, 12/02/2020
Financials
| Next reporting date | March 2, 2021 |
| EPS forecast (this quarter) | -$0.47 |
| Annual revenue (last year) | $339.1M |
| Annual profit (last year) | -$235.3M |
| Net profit margin | -69.38% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
